Barclays share price jumps as Paris HQ shift plan hits tape, buyback keeps focus on Feb results
22 January 2026
1 min read

Barclays share price jumps as Paris HQ shift plan hits tape, buyback keeps focus on Feb results

London, Jan 22, 2026, 08:09 GMT — Regular session

Shares in Barclays jumped almost 2% in early London trading Thursday, pushing the stock near a 52-week peak. The gain came after the bank announced plans to move its European headquarters from Dublin to Paris. 1

This shift is crucial as investors brace for UK bank earnings, grappling with what “post-Brexit Europe” actually entails—costs, regulation, and the locus of decision-making. Barclays has leaned heavily on buybacks, and the market usually reacts harshly if there’s any sign capital returns might taper off.

Barclays aims to shift decision-making closer to its main investment banking hubs in Europe. Francesco Ceccato, CEO of Barclays Europe, said, “We are confident this is the right step forward – both for the entity and for our clients.” The bank is applying to convert into a Societas Europaea, a legal form allowing firms to operate across the EU under unified rules. The conversion is expected by the end of 2026, with the headquarters move planned for the first half of 2027, pending regulatory approval. 2

On Thursday, Barclays revealed another batch of buybacks, repurchasing 2,522,940 ordinary shares on Jan. 21 for cancellation. The volume-weighted average price stood at 475.0654 pence, with individual prices ranging from 470.1 to 479.0 pence, according to the statement. These buybacks shrink the share count, potentially boosting earnings per share if all else remains steady. 3

The early gains follow a shift in sentiment across global markets after U.S. President Donald Trump’s remarks at Davos eased near-term tariff concerns, giving European risk assets a boost. 4

Analysts are pushing the narrative forward. JPMorgan bumped its Barclays price target to 570 pence, calling it its “highest conviction idea” ahead of fourth-quarter results. The bank expects Barclays to chart a course to a 13%-14% sustainable return on tangible equity by 2028, and forecasts Q4 total income near £6.9 billion. JPMorgan also raised its targets for NatWest and Lloyds. 5

The Paris plan faces a lengthy path ahead. It requires several approvals and could trigger one-off expenses that are tough to estimate at this stage. Plus, changes in local oversight might come with conditions attached.

UK banks remain sensitive to shifts in rates and growth. If rate cuts come quicker than anticipated, lending margins could tighten. And any fresh market turmoil—trade policy issues among them—usually takes a swift toll on financial stocks.

Barclays’ full-year 2025 results drop on Feb. 10, offering investors their next major catalyst. The focus will be on guidance, targets, and especially any clearer updates on timing and costs tied to the Paris redomicile effort. 6

Stock Market Today

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

Applied Digital stock jumps 25% as AI data-center names rebound — what’s next for APLD

7 February 2026
Applied Digital Corporation shares jumped 25.52% Friday to $34.95, then slipped to $34.60 after hours. The company reported fiscal Q2 revenue up 250% to $126.6 million and signed leases for 600 MW of data center capacity in North Dakota. Applied Digital broke ground on a new 430‑MW campus in the southern U.S. in January. Financing includes a $100 million promissory note with 8% interest, paid in kind.
Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

Eli Lilly stock pops as FDA targets cheap weight-loss copycats — what to know before Monday

7 February 2026
Eli Lilly shares rose 3.7% to $1,058.18 Friday after the FDA said it would act against telehealth firm Hims & Hers for marketing a $49 compounded weight-loss pill. The move followed a sharp selloff Thursday when Hims announced plans to sell a version of Novo Nordisk’s Wegovy. Investors remain uncertain how aggressively regulators will police copycat drugs and pricing in the obesity drug market.
Seatrium Limited share price slips as DolWin 5 arbitration clouds the next leg for SGX:5E2
Previous Story

Seatrium Limited share price slips as DolWin 5 arbitration clouds the next leg for SGX:5E2

Rio Tinto stock price jumps after record Pilbara shipments as Glencore deadline looms
Next Story

Rio Tinto stock price jumps after record Pilbara shipments as Glencore deadline looms

Go toTop